BTEK:LSE:LSE-iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) (GBP)

ETF | Others |

Last Closing

USD 4.846

Change

+0.07 (+1.36)%

Market Cap

USD 0.49B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-23 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
0R15:LSE SoftBank Group Corp.

N/A

USD 9,217.80B
0R1E:LSE Nintendo Co. Ltd.

N/A

USD 7,596.04B
0R1O:LSE Amazon.com Inc.

+4.00 (+2.20%)

USD 1,607.29B
0R1I:LSE NVIDIA Corp.

+26.15 (+3.08%)

USD 618.20B
LCJD:LSE Amundi MSCI Japan (DR) UCITS E..

+0.21 (+1.19%)

USD 617.54B
LCJP:LSE Lyxor Core MSCI Japan (DR) UCI..

+0.09 (+0.61%)

USD 617.54B
0R1G:LSE Home Depot Inc.

N/A

USD 373.16B
XDJP:LSE Xtrackers Nikkei 225 UCITS ETF..

+20.00 (+0.98%)

USD 348.03B
0QZK:LSE Coca-Cola Co.

-1.05 (-1.69%)

USD 266.08B
0QZO:LSE 0QZO

+1.70 (+1.53%)

USD 258.54B

ETFs Containing BTEK:LSE

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -3.11% 20% F 32% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -3.11% 19% F 31% F
Trailing 12 Months  
Capital Gain -1.43% 22% F 38% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -1.43% 20% F 38% F
Trailing 5 Years  
Capital Gain 31.95% 55% F 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 31.95% 52% F 62% D
Average Annual (5 Year Horizon)  
Capital Gain 50.99% 92% A 93% A
Dividend Return 50.99% 91% A- 93% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 900.63% 6% D- 4% F
Risk Adjusted Return 5.66% 34% F 46% F
Market Capitalization 0.49B 70% C- 60% D-

Annual Financials (GBP)

Quarterly Financials (GBP)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.